CommercialCoverageMedium impact
08.01.93e, Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer Disease
Independence Blue Cross·Neurology, Internal Medicine, Family Medicine +1 more·Medical Policy
Effective date
Jan 1, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross has updated its policy for monoclonal antibodies used to treat Alzheimer's disease, affecting coverage criteria, reimbursement positions, and medical necessity requirements. This change impacts billing for Alzheimer's treatments using monoclonal antibody therapies.
Action Required
By January 1, 2025: Billing team must review the full policy at the provided URL to understand new coverage criteria and medical necessity requirements for monoclonal antibody treatments for Alzheimer's disease. Update billing procedures and prior authorization workflows accordingly. Providers treating Alzheimer's patients should be notified of any new documentation requirements.